Sponsoring the Targeted Cancer Therapy World Congress 2010 is a time and cost-effective opportunity to develop existing and new business.
Sponsorship packages offer your company thought-leadership positioning, branding, and the opportunity to set up face-to-face meetings with hundreds of decision makers from your target market in just 3 working days.
Dr. Ralph Schiess is a biochemist by training and received his Ph.D. from the ETH Zurich. During his doctoral studies his research was focusing on mass spectrometry based proteomics with a special interest in biomarker discovery. He is currently leading the biomarker efforts in the group of Prof. Ruedi Aebersold (ETH Zurich). Furthermore, he is CEO and co-founder of ProteoMediX AG, a company dedicated to enable personalized cancer medicine by bringing together diagnosis and therapy.
Appearing:
DAY 2 WEDNESDAY 22 SEPTEMBER – IMPROVING PRE-CLINICAL & EARLY DEVELOPMENT
12.10pm
Case study: targeted quantitative proteomic strategies for detecting tumour biomarkers in the blood and other body fluids
Using protein profiles determined by mass spectrometry to differentiate between cancerous and non-cancerous cells
Focussing on glycoproteins as a means for developing hypothesis-driven diagnostic methods
Strategies for translating proteomic data into biologically and clinically meaningful information
Dr Ralph Schiess,
Chief Executive Officer and Co-Founder , ProteoMediX AG
Sponsoring Targeted Cancer
Therapy World Congress 2010
is a time and cost-effective opportunity to develop
existing and new business.
Sponsorship packages offer your company thought-leadership positioning, branding, and the opportunity to set up face-to-face meetings with hundreds of decision makers from your target market in just 3 working days.
